Epiliquid
Founded 2021 · 9 employees on LinkedIn · 2 known investors
Epiliquid develops blood-based molecular tests for cancer detection and differential diagnosis using a platform that combines AI-driven methylation biomarker discovery, patented native-DNA assay chemistry, and PCR-based readout. Its technology measures multiple methylation biomarkers in a single PCR reaction and runs on the qPCR and digital PCR instruments clinical laboratories already use, serving precision oncology.
Investors · 2
Frequently asked questions
- What does Epiliquid do?
- Epiliquid develops blood-based molecular tests for cancer detection and differential diagnosis using a platform that combines AI-driven methylation biomarker discovery, patented native-DNA assay chemistry, and PCR-based readout. Its technology measures multiple methylation biomarkers in a single PCR reaction and runs on the qPCR and digital PCR instruments clinical laboratories already use, serving precision oncology.
- Who are Epiliquid's investors?
- Epiliquid's investors include AIR Capital, CITES.